DAB2IP and prostate carcinoma: In prostate cancer, loss of DAB2IP activates the PI3K/AKT pathway and elevates CSC phenotypes, while DAB2IP overexpression inhibits AKT phosphorylation (S473) by directly binding to PI3K-p8532.